ICONIC-LEAD: JNJ-77242113 in Moderate to Severe Plaque Psoriasis

Phase 3, randomised, double-blind trial in plaque psoriasis comparing JNJ-77242113 with Placebo (2 arms). Primary endpoints: Percentage of participants achieving an Investigator's Global Assessment (IGA) score of 0 or 1 and ≥2-grade improvement from baseline to Week 16 and Percentage of participants achieving PASI 90 response at Week 16. Started Jan 2024; status: active, not recruiting.